Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA

Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. The trial will evaluate the efficacy and safety of its novel siRNA asset RBD1016, for the treatment of the rare disease of chronic hepatitis D infection. Ribocure Pharmaceuticals AB, the international research center of Suzhou Ribo Life Science Ltd, […]
Ribocure supports WORLD KIDNEY DAY on March 14th

Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Across the globe, chronic kidney disease (CKD) affects around 700 million people, with 3.1 million deaths attributable to kidney dysfunction, making it the seventh leading cause of mortality worldwide. Low- and middle-income countries bear a disproportionate burden of CKD and kidney failure. Multiple […]
Ribocure supports RARE DISEASE DAY on February 29th

Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Our primary focus lies in addressing unmet medical needs in rare diseases by using precision medicine approaches. We are working on several disease areas that include HDV infection, chylomicronemia syndrome (patients with extremely high triglyceride levels and suffering from frequent pancreatitis), as […]
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Mölndal, Sweden, Kunshan, China and Ingelheim, Germany – 3 January 2024 Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of small […]
Portrait of Li-ming Gan in GoCo News

Our CEO has been portrayed in GoCo news. Here he shared his views on how productive collaboration between industry, academia and health sector may contribute to a successful Swedish life science sector. Read the full article here.
Ribocure Clinic marks milestone with first patient enrolled in a deep phenotyping clinical study

With the ambition to become the leading clinical oligonucleotide research company in Sweden, Ribocure Pharmaceuticals AB established Ribocure Clinic, with a vision to drive excellence in proof of principle/concept clinical trials with an in-house high volume and high quality Ph2 clinical trial unit. Now the first patient has been enrolled in a deep phenotyping study […]
Ribocure Pharmaceuticals and Ribo Life Science announce appointment of John Taylor to Vice President, Head of Global Business Development

John Taylor has joined Ribocure Pharmaceuticals AB as Vice President and Head of Global Business Development. John will lead the global BD team and oversee partnering discussions for Ribocure Pharmaceuticals AB, as well as its parent company Ribo Life Sciences (Ribo) to support its externalization. Li Ming Gan, Ribocure’s CEO and Co-CEO for Ribo said: […]
Ribo announces the latest research news for three siRNA therapeutic drugs at the European Society of Cardiology Congress 2023

Suzhou Ribo Life Science (Ribo) and Ribocure Pharmaceuticals (Ribocure) presented new data from three projects from its cardiovascular pipeline at the European Society of Cardiology Congress (ESC) in Amsterdam on August 25-28, the world’s largest and most influential conference in cardiology. Building on its proprietary liver-targeting platform RIBO-GalSTAR®, highly specific, potent and durable gene silencing […]
Promising data from our HBV program presented at EASL Congress

Thanks EASL for a great meeting and also the opportunity to simultaneously show data from our HBV program, both with regard to its robust preclinical proof of concept data package as well as the hot off the press interim clinical data from the ongoing Ph1b study. Very excited to see the excellent safety data and […]
Ribocure Pharmaceuticals was officially inaugurated on June 30th 2023

We arranged our inauguration ceremony together with both friends and colleagues from academia and industry, as well as many persons that have contributed to the establishment of Ribocure Pharmaceuticals during the past year. Over 75 persons participated, and guests of honor was the leadership team from the mother company Suzhou Ribo Life Science. And who […]